The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients
Status:
Completed
Trial end date:
2020-09-15
Target enrollment:
Participant gender:
Summary
Vasoactive intestinal peptide (VIP) is a peptide of 28 amino acid residues that belongs to
the glucagon/secretin superfamily of peptides. Along with other neuropeptides, such as
calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase-activating polypeptide
(PACAP), it is released from the trigeminal afferents and exerts a strong vasodilating
activity on the cranial vasculature. Especially, it shares 70% structure with PACAP and acts
on the same receptors. But, unlike it, VIP cannot induce a long-lasting vasodilation and has
a modest capability to induce migraine attacks. Whether it may induce migraine-like attacks
in migraine patients, as a twenty-minute infusion of PACAP, is unknown.